Delivery Order SPE2DB20D2014-SPE2DB25FC90J
- Not listed
- The Defense Logistics Agency awarded a $15,269.80 firm fixed price delivery order to AmerisourceBergen Drug Corp for Mounjaro 2.5 mg/0.5 mL pens on August 11, 2025, with an ultimate completion date of August 12, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical will be delivered to the company's...
- The Defense Logistics Agency awarded a $2,239.89 delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 mL pens on September 2, 2025, with completion scheduled for September 3, 2025. This competitive award utilizes firm fixed pricing and represents a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $3,228.25 delivery order on August 29, 2025, for the supply of Mounjaro 7.5 mg/0.5 ml pens with a completion date of September 2, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning the award was competitively issued. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $2,448.81 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Mounjaro 5 mg/0.5 mL pens (0.5 mL units). The contract is scheduled for completion by September 10, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $28,019.96 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 15 mg/0.5 ml pens on August 6, 2025, with completion scheduled for August 7, 2025. The delivery will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $3,437.98 to AmerisourceBergen Drug Corp on July 17, 2025, for the supply of Mounjaro 5 mg/0.5 mL pens (0.5 mL units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 18, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control, aligning with AmerisourceBergen's extensive portfolio of...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,761.93 for Mounjaro 5 mg/0.5 ml pens on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order valued at $1,010.02 to AmerisourceBergen Drug Corp for the supply of Mounjaro 12.5 mg/0.5 mL pens on September 11, 2025, with a completion date of September 12, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded competitively under AmerisourceBergen's existing contract vehicle. The product will be delivered to the company's headquarters location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $3,381.47 delivery order to AmerisourceBergen Drug Corp for Mounjaro 2.5 mg/0.5 mL pens on June 20, 2025, with completion expected by June 23, 2025. This firm fixed-price contract represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control, aligning with AmerisourceBergen's extensive portfolio of pharmaceutical products supplied...
- The Defense Logistics Agency awarded a delivery order valued at $1,225.77 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Mounjaro 5 mg/0.5 mL pens. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC90JDelivery Order
The Defense Logistics Agency awarded a $26,741.23 delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 2.5 mg/0.5 mL pens on September 3, 2025, with completion scheduled for September 4, 2025. This firm fixed-price, non-set-aside contract represents a routine pharmaceutical procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle valued through December 2026. The delivery location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Mounjaro is a diabetes management medication, consistent with AmerisourceBergen's extensive portfolio of pharmaceutical products and medical supplies delivered to federal military and veteran healthcare systems. This delivery order exemplifies the company's role as a critical pharmaceutical distributor supporting DLA's medical supply chain requirements. AmerisourceBergen's competitively awarded contracts with DLA span a broad spectrum of therapeutic categories including specialty medications, vaccines, and medical devices, reflecting the company's established capability to fulfill federal healthcare procurement needs across multiple product lines and delivery scales.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.7k | 9/3/25 |